Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00164450 · ClinicalTrials.gov registry record · NA
TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection
A NA study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- NA
- Development phase
- 158
- Enrollment target
NCT00164450 is a NA study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 158 participants.
The verdict
NCT00164450, a NA study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- NA
- Development phase
- 158 participants
- Enrollment target
Study Summary
Compared to adults, children appear to require higher weight-based doses of rifapentine to acheive comparable drug levels. TBTC Study 26, a study of the effectiveness and tolerability of weekly rifapentine/isoniazid for three months versus daily isoniazid for nine months for the treatment of latent tuberculosis infection, has been amended to include children ages 2-11 based on an initial single-dose study and pharmacokinetic modeling. Study 26PK evaluates the adequacy of the doses chosen for young children enrolled in Study 26 with a single blood draw, 24 hours after the third or subsequent weekly Study 26 dose of rifapentine and isoniazid. An adult control is enrolled for each child enrolled.
Interventions
- DRUG Isoniazid
- DRUG Rifapentine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00164450
The ClinicalTrials.gov registry entry for NCT00164450 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Isoniazid is the first listed.
NCT00164450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00164450 about?
NCT00164450 is a clinical study titled "TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection". Compared to adults, children appear to require higher weight-based doses of rifapentine to acheive comparable drug levels. TBTC Study 26, a study of the effectiveness and tolerability of weekly rifapentine/isoniazid for three months versus daily isoniazid for nine months for the treatment of latent ...
What is the current status of trial NCT00164450?
This trial is currently completed. It is a NA study. The enrollment target is 158 participants. The study started on 2005-09. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00164450?
The interventions under investigation include: Isoniazid (DRUG), Rifapentine (DRUG).
Who is sponsoring clinical trial NCT00164450?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.